![Loader](/assets/loader_gears-10067f3a4c2984639d7edf1d9004a521da8e33a6d776660c0c1ba77f155d23c5.gif)
Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Lumefantrine Action Pathway
Plasmodium falciparum
Drug Action Pathway
Lumefantrine is an antimalarial agent used in combination with artemether for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas. It is thought that administration of lumefantrine with artemether results in cooperate antimalarial clearing effects. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thus thought to provide rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis, as well as causing the accumulation of toxic heme.
References
Lumefantrine Pathway References
Abamecha A, Yilma D, Adissu W, Yewhalaw D, Abdissa A: Efficacy and safety of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. Malar J. 2021 May 6;20(1):213. doi: 10.1186/s12936-021-03745-8.
Pubmed: 33957925
Stover KR, King ST, Robinson J: Artemether-lumefantrine: an option for malaria. Ann Pharmacother. 2012 Apr;46(4):567-77. doi: 10.1345/aph.1Q539. Epub 2012 Apr 10.
Pubmed: 22496476
Silva-Pinto A, Domingos J, Cardoso M, Reis A, Benavente ED, Caldas JP, Conceicao C, Toscano C, Baptista-Fernandes T, Clark TG, Mansinho K, Campino S, Nogueira F: Artemether-lumefantrine treatment failure of uncomplicated Plasmodium falciparum malaria in travellers coming from Angola and Mozambique. Int J Infect Dis. 2021 Sep;110:151-154. doi: 10.1016/j.ijid.2021.07.008. Epub 2021 Jul 7.
Pubmed: 34242769
Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1(Suppl 1):S5. doi: 10.1186/1475-2875-8-S1-S5.
Pubmed: 19818172
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings